A Phase 1 Non-Randomized, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.

开始日期2026-02-20

申办/合作机构

Aligos Therapeutics, Inc.

NCT07342868

/ Recruiting临床1期

A Phase 1 Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety- and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).

开始日期2026-01-30

申办/合作机构

Aligos Therapeutics, Inc.

NCT06963710

/ Recruiting临床2期

A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)

This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.

开始日期2025-07-15

申办/合作机构

Aligos Therapeutics, Inc.

100 项与 Pevifoscorvir sodium 相关的临床结果

登录后查看更多信息

100 项与 Pevifoscorvir sodium 相关的转化医学

登录后查看更多信息

100 项与 Pevifoscorvir sodium 相关的专利（医药）

登录后查看更多信息

项与 Pevifoscorvir sodium 相关的文献（医药）

2026-03-01·The Lancet Gastroenterology & Hepatology

ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial

Article

作者: Chanda, Sushmita ; Ding, Yanhua ; Hou, Jinlin ; Yuen, Man-Fung ; Lin, Tse-I ; Le, Kha ; Blatt, Lawrence ; Niu, Junqi ; Xu, Jia ; Fry, John ; Liang, Xie'er ; Gane, Ed ; Wu, Min ; Jucov, Alina ; Haceatrean, Alexei ; Agarwal, Kosh

BACKGROUND:

ALG-000184 (pevifoscorvir sodium) is a prodrug of the class-E (empty) capsid assembly modulator (CAM), ALG-001075. CAM-Es prevent hepatitis B virus (HBV) replication by inhibiting capsid assembly and pregenomic RNA encapsidation and preventing covalently closed circular DNA (cccDNA) establishment. This part of the study aimed to assess the safety, tolerability, pharmacokinetics and short-term antiviral activity of ALG-000184 in participants with HBeAg-negative and HBeAg-positive chronic HBV infection to determine the subsequent development pathway for this novel therapeutic.

METHODS:

ALG-000184-201 was a phase 1, multicentre, randomised, dose escalation trial designed to evaluate the safety and pharmacokinetics of ALG-000184 in healthy participants (parts 1-2, reported separately) and antiviral activity in treatment-naive or currently not treated participants with chronic HBV infection (part 3, presented here). Eligible participants were 18-65 years old with BMI 18·0-35·0 kg/m², and HBeAg-negative or HBeAg-positive chronic HBV infection with serum HBV DNA concentration more than 2000 IU/mL and serum ALT concentrations less than 5 times the upper limit of normal. Eligible patients were randomly assigned (4:1) to receive 28 days of oral ALG-000184 (10 mg, 50 mg, 100 mg, or 300 mg) or matching placebo once per day. Randomisation was managed via an interactive web response system and other than knowing the dose being evaluated in each cohort, all investigational site personnel and study participants were unaware of treatment assignments. The primary objective of this study was to evaluate the safety and tolerability of ALG-000184 in all randomly assigned participants (intention to treat population) using safety data including all treatment emergence adverse events, physical exam and vital signs findings, 12-lead electrocardiogram, and clinical laboratory findings. This study was registered at ClinicalTrials.gov, NCT04536337, and is complete.

FINDINGS:

Between March 16, 2021, and Oct 13, 2022, 135 participants were screened for inclusion from seven clinical investigational sites in Hong Kong, China, Moldova, New Zealand, and the UK. 76 participants did not meet one or more of the inclusion criteria or met one or more exclusion criteria and 59 participants were enrolled and randomly assigned to receive ALG-000184 10 mg (n=14), 50 mg (n=8), 100 mg (n=16), or 300 mg (n=10) or placebo (n=11). Participants had a median age of 37·0 years (IQR 31·0-45·5). 30 (51%) of 59 patients were male and 29 (49%) were female. 40 (68%) of patients were Asian. 28 (58%) of 48 participants assigned to receive ALG-000184 and seven (64%) of 11 in the placebo group experienced at least one treatment-emergent adverse event (TEAE). The most common TEAEs were increased alanine aminotransferase (ALT; 15 [31%] of 48 participants assigned to ALG-000184 and two [18%] of 11 participants assigned to placebo), increased aspartate aminotransferase (AST) concentrations (12 participants [25%] vs one [9%]), hyperuricemia (five [10%] vs two [18%]), headache (four [8%] vs one [9%]), elevated amylase (three [6%] vs none) and upper respiratory tract infection (three [6%] vs none). There were two serious adverse events unrelated to ALG-000184 (mild spinal pain and spontaneous pneumothorax). There were no deaths in the study. Doses of 10 mg to 300 mg ALG-000184 for 28 days resulted in multi-log reduction of HBV DNA (about 3-4 log₁₀ IU/mL) and HBV RNA (about 0·5-3·0 log₁₀ copies per mL). 19 (83%) of 23 HBeAg-negative participants achieved HBV DNA levels less than the lower limit of quantification (10 IU/mL) and 23 (100%) achieved HBV RNA levels less than the lower limit of quantification (10 copies per mL). Due to higher baseline levels, no HBeAg-positive participant achieved HBV DNA or HBV RNA less than the lower limit of quantification by 28 days. A decrease in HBsAg of 0·5 log₁₀ IU/mL was observed in one HBeAg-positive participant who received 100 mg ALG-000184 and four of eight HBeAg-positive participants who received 300 mg ALG-000184 for 28 days had decreases of 0·2-0·8 log₁₀ IU/mL. ALG-000184 had a dose-dependent linear pharmacokinetic profile.

INTERPRETATION:

ALG-000184 was safe and well tolerated, demonstrated predictable pharmacokinetic properties, and reduced HBV DNA and HBV RNA at all doses regardless of HBeAg status. These results support the evaluation of 300 mg ALG-000184 over longer periods in larger studies to determine its potential role in chronic suppressive therapy, with or without a nucleos(t)ide analogue, or as part of a finite curative regimen.

FUNDING:

Aligos Therapeutics.

2024-12-12·JOURNAL OF MEDICINAL CHEMISTRY

The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075

Article

作者: Zhang, Yafeng ; Smith, David B. ; Chanda, Sushmita ; Geng, Xiu ; Deval, Jerome ; Bassit, Leda ; Beigelman, Leonid N. ; Debing, Yannick ; Raboisson, Pierre ; Vanrusselt, Hannah ; Sanchez, Abel Acosta ; Serebryany, Vladimir ; Welch, Michael ; Hu, Haiyang ; Symons, Julian A. ; Liu, Jyanwei ; Jekle, Andreas ; Gupta, Kusum ; Stoycheva, Antitsa D. ; Tan, Hua ; Kum, Dieudonné Buh ; Williams, Caroline ; Kang, Hyunsoon ; Amblard, Franck ; Hu, Xiaojuan ; Misner, Dinah L. ; Zhang, Liangliang ; McGowan, David C. ; Liu, Cheng ; Blatt, Lawrence M. ; Chou, Lang ; Chen, Xiaoyuan ; Vendeville, Sandrine ; Zhang, Qingling ; Schinazi, Raymond F.

Chronic hepatitis B (CHB) represents a significant unmet medical need with few options beyond lifelong treatment with nucleoside analogues, which rarely leads to a functional cure. Novel agents that reduce levels of HBV DNA, RNA and other viral antigens could lead to better treatment outcomes. The capsid assembly modulator (CAM) class of compounds represents an important modality for chronic suppression and to improve functional cure rates, either alone or in combination. GLP-26 is a potent CAM, which in this work was optimized for potency, safety, and other drug-like properties leading to ALG-001075. ALG-001075 was further advanced through clinical development as the highly soluble prodrug ALG-000184. ALG-000184 is currently being explored in multiple clinical trials in HBV-infected subjects where unprecedented reductions in HBV DNA, RNA and other viral antigens have been observed, making ALG-000184 a promising candidate to become a cornerstone for future chronic suppressive and combination treatment regimens for CHB.

143

项与 Pevifoscorvir sodium 相关的新闻（医药）

2026-05-16

·今日头条

国产乙肝新药扎堆进入3期临床！核衣壳组装调节剂这个赛道，中国药企正领跑全球 “得了乙肝，是不是这辈子都要一直吃药了？” 这个问题，困扰着全球超过2.5亿的慢乙肝患者。现有的核苷类似物和干扰素虽能把病毒压下去，却很难彻底“摘掉”乙肝的帽子，患者往往需要终身服药。但现在，一个叫做“核衣壳组装调节剂（

国产乙肝新药扎堆进入3期临床！核衣壳组装调节剂这个赛道，中国药企正领跑全球 “得了乙肝，是不是这辈子都要一直吃药了？” 这个问题，困扰着全球超过2.5亿的慢乙肝患者。现有的核苷类似物和干扰素虽能把病毒压下去，却很难彻底“摘掉”乙肝的帽子，患者往往需要终身服药。但现在，一个叫做“核衣壳组装调节剂（CAM）”的全新赛道，正让无数慢乙肝患者看到了新的希望。简单理解：这药是怎么“破局”的？我们可以把乙肝病毒想象成一个需要不断“建造新房”来繁殖自身的入侵者。而“核衣壳组装调节剂”就像是一个精准的“违章建筑拆除队”。它不直接去杀病毒，而是干扰病毒建造保护性外壳的过程，导致病毒只能造出“空壳房子”或者畸形结构，从而让病毒无法正常复制生存。更重要的是，这类药还能在病毒生命周期的多个阶段发挥作用，进而实现“多个环节同时打击”，这正是其备受关注的原因。目前，全球不少药企都布局了这一赛道，而中国的研发力量正以“领跑”的姿态，将多款药物推进到了临床后期。冲刺3期：国产三巨头，谁会是首个“撞线者”？在竞争最激烈的临床3期阶段，国产新药已经形成了“三驾马车”齐头并进的格局，中国速度不容小觑。 1. Canocapavir（ZM-H1505R）：国产“明星选手” 研发方为上海挚盟医药。这款药在2025年正式获批启动3期关键性临床，且在此前已因出色数据被纳入了“突破性治疗品种”。它的3期研究计划招募1300名患者，规模非常大。能走到3期，意味着它离患者的距离已经越来越近了。 2. GST-HG141（奈瑞可韦）：研发速度惊人由广生堂研发。这款药在2025年同样“动作神速”：5月底召开3期临床研究者会议，7月底首例受试者便成功入组。它同样因前期出色表现获得了“突破性治疗药物”认定，显示出巨大的治疗潜力。 3. Morphothiadin（GLS4，甲磺酸莫非赛定）：潜在的“First-in-Class” 研发方为东阳光药/康哲药业。这款药的地位非常特殊，它被认为是全球同靶点中研发进展最快的化合物之一，并且是全球首个在临床试验中被证实可明确抑制乙肝表面抗原的小分子。有分析曾乐观预测其有望在2024年获批上市，虽然进度稍有延迟，但依然是赛道里不可忽视的实力派选手。潜力无限的2期“后备军” 除了3期的“先头部队”，2期也有一批各具特色的潜力股，不过它们的进展各不相同。 1. ALG-000184（Aligos）：最具潜力的“头号种子” 研发方为美国Aligos公司。这款药被看作是“同类最佳/首创”候选药物。2025年8月，其正式启动了名为“B-SUPREME”的全球多中心2期临床研究。在前期1期长达96周的给药研究中，它不仅展示了强大的抗病毒活性，甚至对乙肝表面抗原等关键指标都有持续的降低作用，市场期待值极高。 2. Bersacapavir（JNJ-56136379） & Vebicorvir（ABI-H0731）：遭遇挫折的先行者研发方分别为强生和Assembly Biosciences。这两款是CAM领域的“前辈”，可惜都在最近的赛跑中摔了跟头：强生的Bersacapavir临床2期研究已显示“终止”，而Assembly的Vebicorvir 2期研究也遭遇了部分终止。跨国药企巨头的这一“退赛”，也从侧面印证了新药研发的风险之高，以及国产药物如今能稳步推进的不易。悄然起步的1期“新兵” 在1期阶段，齐鲁制药的HBV-CAM-005和中美华东的ZY-HBV-001也在加紧推进早期研究，为这个赛道提供源源不断的后备力量。结语：这条路，曙光已现从国产“三驾马车”齐头并进，到新一代药物在2期展现的惊人潜力，再到部分早期产品的受挫，乙肝功能性治愈的探索之路，正在曲折中走向光明。目前，我们距离彻底“摘掉”乙肝的帽子仍有距离，但科学家和药企们从未停止前进。期待这些在研的新药早日传来佳音，让全球亿万慢乙肝患者能够真正迎来“功能性治愈”的那一天。

2026-05-15

·今日头条

国产乙肝新药扎堆进入3期临床！这个赛道，中国药企正领跑全球 “得了乙肝，是不是这辈子都要一直吃药了？” 这个问题，困扰着全球超过2.5亿的慢乙肝患者。现有的核苷类似物和干扰素虽能把病毒压下去，却很难彻底“摘掉”乙肝的帽子，患者往往需要终身服药。但现在，一个叫做“核衣壳组装调节剂（CAM）”的全新

国产乙肝新药扎堆进入3期临床！这个赛道，中国药企正领跑全球 “得了乙肝，是不是这辈子都要一直吃药了？” 这个问题，困扰着全球超过2.5亿的慢乙肝患者。现有的核苷类似物和干扰素虽能把病毒压下去，却很难彻底“摘掉”乙肝的帽子，患者往往需要终身服药。但现在，一个叫做“核衣壳组装调节剂（CAM）”的全新赛道，正让无数慢乙肝患者看到了新的希望。简单理解：这药是怎么“破局”的？我们可以把乙肝病毒想象成一个需要不断“建造新房”来繁殖自身的入侵者。而“核衣壳组装调节剂”就像是一个精准的“违章建筑拆除队”。它不直接去杀病毒，而是干扰病毒建造保护性外壳的过程，导致病毒只能造出“空壳房子”或者畸形结构，从而让病毒无法正常复制生存。更重要的是，这类药还能在病毒生命周期的多个阶段发挥作用，进而实现“多个环节同时打击”，这正是其备受关注的原因。目前，全球不少药企都布局了这一赛道，而中国的研发力量正以“领跑”的姿态，将多款药物推进到了临床后期。冲刺3期：国产三巨头，谁会是首个“撞线者”？在竞争最激烈的临床3期阶段，国产新药已经形成了“三驾马车”齐头并进的格局，中国速度不容小觑。 1. Canocapavir（ZM-H1505R）：国产“明星选手” 研发方为上海挚盟医药。这款药在2025年正式获批启动3期关键性临床，且在此前已因出色数据被纳入了“突破性治疗品种”。它的3期研究计划招募1300名患者，规模非常大。能走到3期，意味着它离患者的距离已经越来越近了。 2. GST-HG141（奈瑞可韦）：研发速度惊人由广生堂研发。这款药在2025年同样“动作神速”：5月底召开3期临床研究者会议，7月底首例受试者便成功入组。它同样因前期出色表现获得了“突破性治疗药物”认定，显示出巨大的治疗潜力。 3. Morphothiadin（GLS4，甲磺酸莫非赛定）：潜在的“First-in-Class” 研发方为东阳光药/康哲药业。这款药的地位非常特殊，它被认为是全球同靶点中研发进展最快的化合物之一，并且是全球首个在临床试验中被证实可明确抑制乙肝表面抗原的小分子。有分析曾乐观预测其有望在2024年获批上市，虽然进度稍有延迟，但依然是赛道里不可忽视的实力派选手。潜力无限的2期“后备军” 除了3期的“先头部队”，2期也有一批各具特色的潜力股，不过它们的进展各不相同。 1. ALG-000184（Aligos）：最具潜力的“头号种子” 研发方为美国Aligos公司。这款药被看作是“同类最佳/首创”候选药物。2025年8月，其正式启动了名为“B-SUPREME”的全球多中心2期临床研究。在前期1期长达96周的给药研究中，它不仅展示了强大的抗病毒活性，甚至对乙肝表面抗原等关键指标都有持续的降低作用，市场期待值极高。 2. Bersacapavir（JNJ-56136379） & Vebicorvir（ABI-H0731）：遭遇挫折的先行者研发方分别为强生和Assembly Biosciences。这两款是CAM领域的“前辈”，可惜都在最近的赛跑中摔了跟头：强生的Bersacapavir临床2期研究已显示“终止”，而Assembly的Vebicorvir 2期研究也遭遇了部分终止。跨国药企巨头的这一“退赛”，也从侧面印证了新药研发的风险之高，以及国产药物如今能稳步推进的不易。悄然起步的1期“新兵” 在1期阶段，齐鲁制药的HBV-CAM-005和中美华东的ZY-HBV-001也在加紧推进早期研究，为这个赛道提供源源不断的后备力量。不过，目前暂未搜索到关于上述两款药物独立的、最新的临床进展信息，其具体阶段需要持续关注其官方动态。结语：这条路，曙光已现从国产“三驾马车”齐头并进，到新一代药物在2期展现的惊人潜力，再到部分早期产品的受挫，乙肝功能性治愈的探索之路，正在曲折中走向光明。目前，我们距离彻底“摘掉”乙肝的帽子仍有距离，但科学家和药企们从未停止前进。期待这些在研的新药早日传来佳音，让全球亿万慢乙肝患者能够真正迎来“功能性治愈”的那一天。

2026-05-13

·BioSpace

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at . Details on the abstracts are as follows: Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection Abstract #: 588 Title: Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy Presenter: Professor Lung-Yi Loey Mak, MBBS(HK), MD(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine), FRCP (Glasg), FRCP (Edin), FRCP, Clinical Assistant Professor at The University of Hong Kong Date/Time: May 27, 2026 at 8:30am – 5:00pm CET Session: Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Abstract #: 602 Title: Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong Date/Time: May 27, 2026 at 8:30am – 5:00pm CET Session: Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Abstract #: 586 Title: Population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection Presenter: Kha Le, PhD Date/Time: May 27, 2026 at 8:30am – 5:00pm CET Session: Viral Hepatitis B and D: New therapies, unapproved therapies or strategies Abstract #: 570 Title: ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development Presenter: Yannick Debing, PhD Date/Time: May 28, 2026 at 8:30am – 5:00pm CET Session: Viral Hepatitis: Experimental and pathophysiology Abstract #: 634 Title: Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments Presenter: Professor Barbara Testoni, PhD, HDR, DR2 INSERM - Team Leader "Hepatitis Viruses and Liver pathogenesis". Université Claude Bernand Lyon 1, Inserm UMR 1350 - PaThLiv Date/Time: May 28, 2026 at 8:30am – 5:00pm CET Session: Viral Hepatitis: Experimental and pathophysiology ALG-170675: Potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection Abstract #: 587 Title: The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities Presenter: Jin Hong, PhD Date/Time: May 28, 2026 at 8:30am – 5:00pm CET Session: Viral Hepatitis: Experimental and pathophysiology ALG-055009: Potential best-in-class small molecule THR- β Agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Abstract #: 184 Title: Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists Presenter: Xuan Luong, PhD Date/Time: May 30, 2025 at 8:30am – 4:00pm CET Session: Poster - MASLD: Experimental and pathophysiology Preclinical Abstract #: 606 Title: Antisense oligonucleotide-based strategy to target hepatitis delta virus infections Presenter: Julie Lucifora, PhD, HDR, Director of Research, INSERM, CIRI - Centre International de Recherche en Infectiologie Date/Time: May 28, 2026 at 12:45 – 1:45pm CET; May 28, 2026 at 8:30am – 5:00pm CET Session: Poster Tour – Track 8 – Viral Hepatitis; Viral Hepatitis: Experimental and pathophysiology Abstract #: 610 Title: Discovery of novel HDV entry inhibitors with selectivity over bile acid inhibition Presenter: David McGowan, MS Date/Time: May 28, 2026 at 8:30am – 5:00pm CET Session: Viral Hepatitis: Experimental and pathophysiology Abstract #: 620 Title: Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer Presenter: Heleen Roose, PhD Date/Time: May 28, 2026 at 8:30am – 5:00pm CET Session: Viral Hepatitis: Experimental and pathophysiology About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses. For more information, please visit or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Investor Contact Aligos Therapeutics, Inc. Jordyn Tarazi Vice President, Investor Relations & Corporate Communications +1 (650) 910-0427 jtarazi@aligos.com Media Contact Inizio Evoke Jake Robison Vice President Jake.Robison@inizioevoke.com

临床结果siRNA临床2期

100 项与 Pevifoscorvir sodium 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性乙型肝炎	临床2期	美国	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	中国	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	保加利亚	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	加拿大	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	法国	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	中国香港	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	意大利	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	摩尔多瓦	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	新西兰	Aligos Therapeutics, Inc.	2025-07-15
慢性乙型肝炎	临床2期	罗马尼亚	Aligos Therapeutics, Inc.	2025-07-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04536337 (Pubmed) 人工标引	临床1期	慢性乙型肝炎	59	ALG-000184	簾繭壓範壓選顧積糧膚(網襯淵鹽範鏇憲願顧艱) = 簾鏇願繭鹹積醖積鬱構膚艱觸壓遞築廠願製襯 (襯齋選憲壓觸鑰醖淵鑰 ) 更多	积极	2026-01-16
				Placebo	糧蓋餘觸觸範鹽廠鬱膚(選齋壓夢網窪獵窪簾簾) = 齋簾鏇襯願襯膚願淵鬱醖鏇壓齋艱壓襯夢鬱遞 (鏇遞鏇鹹構鬱繭築繭鏇 )
NCT04536337 (GlobeNewswire) 人工标引	临床1期	慢性乙型肝炎	11	ALG-000184ALG-000184 300 mg monotherapy (HBeAg+)	製鹽鹽襯壓積艱膚範遞(夢窪糧獵鏇獵鹽蓋選膚) = 築願鹹顧觸醖遞構簾製壓廠範糧廠獵醖鏇齋淵 (築膚獵壓獵簾獵衊築鬱 ) 更多	积极	2025-03-26
				ALG-000184 300 mg monotherapy (HBeAg-)	製鹽鹽襯壓積艱膚範遞(淵築構廠鏇遞構顧窪繭) = 網糧餘齋艱構夢範遞糧獵膚窪築鏇觸膚襯膚膚 (壓顧醖鑰獵廠選憲鬱鏇 )
NCT04536337 (ALG-000184-201, EASL2024) 人工标引	临床1期	慢性乙型肝炎 \| 完全性房室传导阻滞	11	ALG-000184 300 mg	夢壓襯糧遞繭製選鬱壓(觸窪淵製鏇窪網艱鏇齋) = 淵製膚襯醖製餘積選選積淵範淵範艱構鹹繭獵 (積醖廠膚鏇壓膚繭糧蓋 ) 更多	积极	2024-06-01
NCT04536337 (ALG-000184-201, EASL2024) 人工标引	临床1期	慢性乙型肝炎	22	ALG-000184 + Entecavir	鹽遞夢齋築遞顧獵積網(構築壓糧選觸鹽選壓齋) = 齋艱鏇衊鏇網積鹹衊憲願膚壓構顧構網觸製鏇 (餘蓋築壓鹽壓鬱鬱憲鹽, 0.4) 更多	积极	2024-06-01
				ALG-000184	-
NCT04536337 (ALG-000184-201, EASL2024) 人工标引	临床1期	慢性乙型肝炎	22	ALG-000184 + ETV	鑰範艱齋鑰窪醖鬱願襯(製壓淵窪製積構鏇繭製) = In a multiple regression model, baseline HBsAg (< or ≥4 log10 IU/ ml) and steady state plasma ALG-001075 exposure (AUC or Ctrough) statistically significantly predicted change from baseline in HBsAg at week 24 (p < 0.00018, R2 = 0.65). 遞糧範艱網襯窪觸繭鑰 (餘夢網築憲觸齋蓋鏇醖 ) 更多	积极	2024-06-01
				ALG-000184
GlobeNewswire 人工标引	临床1期	慢性乙型肝炎	-	ALG-000184 ± entecavir	繭糧蓋齋艱餘顧鹽構醖(鑰顧糧製範構鹹觸網蓋) = Oral dosing with 300 mg of ALG-000184 ± entecavir (ETV) for up to 48 weeks in untreated HBeAg positive chronic hepatitis B patients demonstrated a favorable safety profile and greater suppression of HBV DNA and RNA versus ETV alone 鹽憲蓋衊餘繭網艱廠餘 (醖廠製鑰積鬱夢壓鹽鑰 ) 更多	积极	2023-12-07
NCT04536337 (ALG-000184-201, AASLD2023)	临床1期	慢性乙型肝炎 HBeAg+	-	ALG-000184 + Entecavir (ETV)	構壓網蓋鹹遞醖積製繭(齋顧觸憲襯蓋糧遞鏇襯) = Grade 4 TEAE of ALT elevation, which peaked at 416 U/L (10.1xULN) on Day 171 顧淵構夢積窪淵願築艱 (簾簾艱蓋繭醖鏇網襯製 )	-	2023-11-10
NCT04536337 (Corporate Publications) 人工标引	临床1期	慢性乙型肝炎	-	ALG-000184	鹽選襯製艱夢觸築醖膚(膚鹽齋蓋積範獵糧積淵) = No Grade ≥2 treatment emergent laboratory abnormalities 蓋艱膚願醖鹹衊製窪獵 (鑰襯襯艱艱醖鬱蓋顧襯 )	积极	2022-04-29
				Placebo